Gabrail Cancer Center

Recent publications and citations

Top Concepts

Top subject area publications in last 5 years

Collaboration Analysis

Publications from 2021 to 2026

Latest Publications

Filter IconFilter

Showing 10 of 31 papers

  • Research Article
  • Citations5

Phase Ib Basket Expansion Trial and Alternative-Schedule Dose-Escalation Study of ATR Inhibitor Elimusertib in Advanced Solid Tumors with DNA Damage Response Defects.

  • Jun 16, 2025
  • Cancer discovery
  • Timothy A Yap +21
  • Research Article
  • Citations8

Lisaftoclax (APG-2575) Demonstrates Activity and Safety When Given with Accelerated Ramp-up and then Combined with Acalabrutinib or Rituximab in Patients (pts) with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Including Those with Prior Exposure to Venetoclax

  • Nov 05, 2024
  • Blood
  • Matthew S Davids +36
  • Abstract

A Phase 1 Dose-escalation and Expansion Study of CUE-101, Given As Monotherapy in 3rd Line and in Combination with Pembrolizumab in 1st Line Recurrent/Metastatic (R/M) HPV16+ Head and Neck Cancer Patients

  • Mar 14, 2024
  • International Journal of Radiation Oncology, Biology, Physics
  • A.d Colevas +19
  • Research Article

Phase 1/2 dose escalation and dose expansion study of TransCon IL-2 β/γ alone or in combination with pembrolizumab: Initial results from dose escalation.

  • Jun 01, 2023
  • Journal of Clinical Oncology
  • Alexander Starodub +14
  • Research Article
  • Citations11

Early efficacy evaluation of ORIN1001, a first in class IRE1 alpha inhibitor, in advanced solid tumors.

  • Jun 01, 2023
  • Journal of Clinical Oncology
  • Mothaffar F Rimawi +9
  • Open Access
  • Abstract
  • Citations1

EP294/#883 Elimusertib, an oral ataxia telangiectasia and RAD3-related inhibitor, in advanced gynecologic cancers with DNA damage response defects

  • Dec 01, 2022
  • International Journal of Gynecologic Cancer
  • David S Tan +18
  • Open Access
  • Abstract
  • Citations16

Lisaftoclax (APG-2575) Safety and Activity As Monotherapy or Combined with Acalabrutinib or Rituximab in Patients (pts) with Treatment-Naïve, Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (R/R CLL/SLL): Initial Data from a Phase 2 Global Study

  • Nov 15, 2022
  • Blood
  • Matthew S Davids +37
  • Open Access
  • Research Article
  • Citations9

Safety and pharmacokinetics of docetaxel in combination with pegvorhyaluronidase alfa in patients with non‐small cell lung cancer

  • Jul 30, 2021
  • Clinical and Translational Science
  • Thomas Heineman +8
  • Abstract
  • Citations26

Anti Tumor Activity Of Selinexor (KPT-330), A First-In-Class Oral Selective Inhibitor Of Nuclear Export (SINE) XPO1/CRM1 Antagonist In Patients (pts) With Relapsed / Refractory Multiple Myeloma (MM) Or Waldenstrom's Macroglobulinemia (WM)

  • Jul 07, 2021
  • Blood
  • Martin Gutierrez +23
  • Research Article
  • Citations25

A phase 1/2 trial of ORIN1001, a first-in-class IRE1 inhibitor, in patients with advanced solid tumors.

  • May 20, 2021
  • Journal of Clinical Oncology
  • Nashat Y Gabrail +12
Cactus Communications logo

Copyright 2026 Cactus Communications. All rights reserved.